Degarelix studies: 60 papers with results
Page 2 of 2
Degarelix has 289 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.
- Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
Kim K · Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
Animal study (in vivo) · mouse · 1 result
- Follicle-stimulating hormone promotes growth of human prostate cancer cell line-derived tumor xenografts.
Oduwole OO · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
Animal study (in vivo) · mouse · 2 results
- Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance.
Schwach G · European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2004
Animal study (in vivo) · rat · 13 results
- Endothelial dysfunction after androgen deprivation therapy and the possible underlying mechanisms.
Teoh JY · The Prostate · 2022
Animal study (in vivo) · rat · 5 results
- GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.
Cucchiara V · Molecular cancer therapeutics · 2019
Animal study (in vivo) · mouse · 8 results
- Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Samant MP · Journal of medicinal chemistry · 2006
Animal study (in vivo) · rat · 2 results
- Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples.
Koechling W · British journal of clinical pharmacology · 2010
Ex vivo tissue · 2 results
- Sertoli-secreted FGF-2 induces PFKFB4 isozyme expression in mouse spermatogenic cells by activation of the MEK/ERK/CREB pathway.
Gómez M · American journal of physiology. Endocrinology and metabolism · 2012
Ex vivo tissue · rat · 1 result
- In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth.
Sakai M · PloS one · 2015
In vitro (cells) · 9 results
- Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
Chen DY · The Prostate · 2021
In vitro (cells) · 2 results